PL4346900T3 - Kompozycja zawierająca estr alfa-tokoferolu w celu zmniejszenia ryzyka porodu przedwczesnego - Google Patents

Kompozycja zawierająca estr alfa-tokoferolu w celu zmniejszenia ryzyka porodu przedwczesnego

Info

Publication number
PL4346900T3
PL4346900T3 PL22729540.9T PL22729540T PL4346900T3 PL 4346900 T3 PL4346900 T3 PL 4346900T3 PL 22729540 T PL22729540 T PL 22729540T PL 4346900 T3 PL4346900 T3 PL 4346900T3
Authority
PL
Poland
Prior art keywords
tocopherol
alpha
ester
risk
reducing
Prior art date
Application number
PL22729540.9T
Other languages
English (en)
Inventor
Giorgio Panin
Original Assignee
Hulka S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hulka S.R.L. filed Critical Hulka S.R.L.
Publication of PL4346900T3 publication Critical patent/PL4346900T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
PL22729540.9T 2021-05-27 2022-05-16 Kompozycja zawierająca estr alfa-tokoferolu w celu zmniejszenia ryzyka porodu przedwczesnego PL4346900T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000013898A IT202100013898A1 (it) 2021-05-27 2021-05-27 Composizione comprendente un estere di alfa-tocoferolo per la riduzione del rischio di parto pretermine
PCT/EP2022/063177 WO2022248269A1 (en) 2021-05-27 2022-05-16 Composition comprising an ester of alpha-tocopherol for reducing the risk of preterm birth

Publications (1)

Publication Number Publication Date
PL4346900T3 true PL4346900T3 (pl) 2025-03-31

Family

ID=77801802

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22729540.9T PL4346900T3 (pl) 2021-05-27 2022-05-16 Kompozycja zawierająca estr alfa-tokoferolu w celu zmniejszenia ryzyka porodu przedwczesnego

Country Status (22)

Country Link
US (1) US12453714B2 (pl)
EP (1) EP4346900B1 (pl)
AU (1) AU2022283507A1 (pl)
BR (1) BR112023024736A2 (pl)
CA (1) CA3219732A1 (pl)
CL (1) CL2023003488A1 (pl)
DK (1) DK4346900T3 (pl)
ES (1) ES3015526T3 (pl)
FI (1) FI4346900T3 (pl)
GE (2) GEP20247621B (pl)
HR (1) HRP20250267T1 (pl)
HU (1) HUE070246T2 (pl)
IT (1) IT202100013898A1 (pl)
LT (1) LT4346900T (pl)
MA (1) MA64808B1 (pl)
MX (1) MX2023013918A (pl)
PL (1) PL4346900T3 (pl)
PT (1) PT4346900T (pl)
RS (1) RS66552B1 (pl)
SI (1) SI4346900T1 (pl)
SM (1) SMT202500076T1 (pl)
WO (1) WO2022248269A1 (pl)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3763075B2 (ja) 1998-04-24 2006-04-05 サンスター株式会社 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物
WO2011150393A2 (en) 2010-05-28 2011-12-01 Bmg Hematology Llc Methods for improving maternal and fetal health
CN101999426B (zh) * 2010-09-25 2011-11-30 昆明医学院 孕妇营养饼干
IL230419A0 (en) 2013-05-23 2014-04-30 Naveh Pharma 1996 Ltd Products containing magnesium and their uses
LT3209294T (lt) * 2014-10-22 2019-10-25 Bio Lo Ga Srl Farmacinė kompozicija, skirta panaudoti nosies gleivinės trofizmo padidinimui
JP2018522854A (ja) * 2015-06-22 2018-08-16 リポカイン インコーポレーテッド 17−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法
WO2017081725A1 (ja) * 2015-11-09 2017-05-18 花王株式会社 口腔用組成物
TWI912235B (zh) 2017-12-01 2026-01-21 瑞士商雀巢製品股份有限公司 母體補充劑

Also Published As

Publication number Publication date
AU2022283507A1 (en) 2023-11-30
GEP20247621B (en) 2024-05-13
EP4346900B1 (en) 2025-01-29
PT4346900T (pt) 2025-02-19
BR112023024736A2 (pt) 2024-02-15
SI4346900T1 (sl) 2025-05-30
DK4346900T3 (da) 2025-02-17
EP4346900A1 (en) 2024-04-10
HUE070246T2 (hu) 2025-05-28
RS66552B1 (sr) 2025-03-31
WO2022248269A1 (en) 2022-12-01
GEAP202316392A (en) 2023-12-11
MX2023013918A (es) 2023-12-08
LT4346900T (lt) 2025-03-25
MA64808B1 (fr) 2025-02-28
CA3219732A1 (en) 2022-12-01
CL2023003488A1 (es) 2024-05-24
SMT202500076T1 (it) 2025-03-12
HRP20250267T1 (hr) 2025-04-11
US20240261255A1 (en) 2024-08-08
FI4346900T3 (fi) 2025-03-05
IT202100013898A1 (it) 2022-11-27
ES3015526T3 (en) 2025-05-06
US12453714B2 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
EP3352670B8 (en) Method and system for assessing healing of tissue
GB2585479B (en) Reduction of the effects of latency for extended reality experiences
PH12015501572A1 (en) Veterinary supplements
EP4281084A4 (en) Compounds and methods for reducing Dux4 expression
AU2010306870A8 (en) Reducing the risk of pathological effects of traumatic brain injury
EP4013889A4 (en) SCHIZOPHRENIA RISK ASSESSMENT SYSTEM AND METHOD
IL318706A (en) Compositions and methods for inducing proptosis
EP3479113A4 (en) METHOD AND SYSTEM FOR REDUCING THE EFFECTS OF CROSSWAY OF PILLAR OUTLET
SI4346900T1 (sl) Sestava, ki vsebuje ester alfa-tokoferola za zmanjšanje tveganja prezgodnjega poroda
GB202102798D0 (en) Controller for an aircraft system
EP3993464A4 (en) Method for reducing nas signaling of lcs and lpp procedures
SG11202007786WA (en) Composition and composition for lowering blood pressure and/or reducing neutral fats
EP3616705A4 (en) COMPOSITION WITH AMOMUM VILLOSUM TO IMPROVE THE PREVENTION AND TREATMENT OF FATTY LIVER
EP3621462A4 (en) COMPOSITION FOR BETTER ABSORPTION OF COMPLEMENTS
EP3366346A4 (en) COSMETIC METHOD FOR REDUCING OR PREVENTING ACCUMULATION OF ADIPOSE TISSUE
HK40091231A (en) Method for determining risk of pre-term birth
PL4308929T3 (pl) Sposób diagnozy in vitro infekcji
HK40085033A (en) Tafoxiparin for the treatment of preeclampsia
HK40110478A (en) Compositions and methods for inhibiting the expression of tmigd2
SI3171873T1 (sl) Sestavek, ki obsega ester alfa-tokoferola za preprečevanje in zdravljenje alergijskega rinitisa
AU2021900576A0 (en) Composition for the treatment of skin conditions such as eczema
HK40102696A (en) Compositions for the treatment of skin conditions
AU2023902472A0 (en) Methods and systems for assessing the presence of traumatic brain injury
HK40116106A (en) Tetrahydrobenzoazepinones and related analogs for inhibiting yap/taz-tead
GB202210304D0 (en) Composition comprising cannabidiol